Skip to main content

Advertisement

Log in

Hearing of Otof-deficient mice restored by trans-splicing of N- and C-terminal otoferlin

  • Original Investigation
  • Published:
Human Genetics Aims and scope Submit manuscript

Abstract

Mutations to the OTOF gene are among the most common reasons for auditory neuropathy. Although cochlear implants are often effective in restoring sound transduction, there are currently no biological treatments for individuals with variants of OTOF. Previous studies have reported the rescue of hearing in DFNB9 mice using OTOF gene replacement although the efficacy needs improvement. Here, we developed a novel dual-AAV-mediated gene therapy system based on the principles of protein trans-splicing, and we show that this system can reverse bilateral deafness in Otof –/– mice after a single unilateral injection. The system effectively expressed exogenous mouse or human otoferlin after injection on postnatal day 0–2. Human otoferlin restored hearing to near wild-type levels for at least 6 months and restored the release of synaptic vesicles in inner hair cells. Our study not only provides a preferential clinical strategy for the treatment of OTOF-related auditory neuropathies, but also describes a route of development for other large-gene therapies and protein engineering techniques.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

Download references

Acknowledgements

This work was supported by the National Key Research and Development Program of China (2020YFA0908201), the National Natural Science Foundation of China (82171148), the Clinical Research Plan of SHDC (SHDC2020CR4083), the Science and Technology Commission of Shanghai Municipality (21S11905100), the Special Project for Clinical Research in Health Industry of Shanghai Municipal Health Commission (20224Z0003), the Excellent Doctors-Excellent Clinical Researchers Program of Eye & ENT Hospital of Fudan University (SYB202005), and the “Shuguang Program” supported by the Shanghai Education Development Foundation and the Shanghai Municipal Education Commission (20SG08). We thank Shanghai Refreshgene Therapeutics Co., Ltd. for suggestions and assistance with the experiments.

Funding

The National Key Research and Development Program of China, 2020YFA0908201, Yilai Shu, the National Natural Science Foundation of China, 82171148, Yilai Shu, the Clinical Research Plan of SHDC, SHDC2020CR4083, Yilai Shu, the Science and Technology Commission of Shanghai Municipality, 21S11905100, Yilai Shu, the Special Project for Clinical Research in Health Industry of Shanghai Municipal Health Commission, 20224Z0003, Yilai Shu, the Excellent Doctors-Excellent Clinical Researchers Program of Eye & ENT Hospital of Fudan University, SYB202005, Yilai Shu, the “Shuguang Program” supported by the Shanghai Education Development Foundation and the Shanghai Municipal Education Commission, 20SG08, Yilai Shu

Author information

Authors and Affiliations

Authors

Contributions

YS, HL, and WW: developed and supervised the project. HT and YS: jointly conceived the project. HT designed experiments and analyzed the data. HW, JL, MX, and FW: performed the in vivo experiments and the partial data analysis. HT: conducted the structural prediction. SW, HT, and SH: conducted the in vitro experiments. HT, YS, and SH: wrote the manuscript. HT, YS, SH, HW, SW, KG, YC, and DW: reviewed and revised the manuscript. All the authors read and approved the final manuscript.

Corresponding authors

Correspondence to Wuqing Wang, Huawei Li or Yilai Shu.

Ethics declarations

Conflict of interests

All the authors declare no competing interests. Kaiyu Gao is currently an employee of Shanghai Refreshgene Therapeutics Co., Ltd.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplemental information can be found online at (DOCX 6766 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, H., Wang, H., Wang, S. et al. Hearing of Otof-deficient mice restored by trans-splicing of N- and C-terminal otoferlin. Hum Genet 142, 289–304 (2023). https://doi.org/10.1007/s00439-022-02504-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00439-022-02504-2

Navigation